Adage Capital Partners Gp, L.L.C. Eiger Bio Pharmaceuticals, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.04 - $9.66 $533,332 - $852,978	-88,300 Reduced 8.41%	961,700 $7.24 Million
Q2 2022 Aug 15, 2022	SELL	$4.99 - $8.96 $3.24 Million - $5.82 Million	-650,000 Reduced 38.24%	1,050,000 $6.62 Million
Q1 2022 May 16, 2022	BUY	$3.84 - $9.74 $6.53 Million - $16.6 Million	1,700,000 New	1,700,000 $14.1 Million
Q4 2020 Feb 16, 2021	SELL	$7.98 - $12.29 $2 Million - $3.07 Million	-250,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$7.96 - $12.42 $1.99 Million - $3.11 Million	-250,000 Reduced 50.0%	250,000 $2.04 Million
Q2 2020 Aug 14, 2020	BUY	$5.4 - $13.37 $1.66 Million - $4.1 Million	306,626 Added 158.57%	500,000 $4.8 Million
Q1 2020 May 15, 2020	SELL	$4.91 - $14.7 $9.98 Million - $29.9 Million	-2,031,626 Reduced 91.31%	193,374 $1.32 Million
Q2 2019 Aug 14, 2019	BUY	$9.54 - $14.96 $4.29 Million - $6.73 Million	450,000 Added 25.35%	2,225,000 $23.6 Million
Q4 2018 Feb 14, 2019	BUY	$8.63 - $12.4 $9.43 Million - $13.6 Million	1,092,800 Added 160.19%	1,775,000 $18 Million
Q2 2018 Aug 14, 2018	BUY	$8.3 - $16.8 $5.66 Million - $11.5 Million	682,200 New	682,200 $8.32 Million

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.